CN116803417B - Vaginal mucosa repair composition and application thereof - Google Patents
Vaginal mucosa repair composition and application thereof Download PDFInfo
- Publication number
- CN116803417B CN116803417B CN202311071998.XA CN202311071998A CN116803417B CN 116803417 B CN116803417 B CN 116803417B CN 202311071998 A CN202311071998 A CN 202311071998A CN 116803417 B CN116803417 B CN 116803417B
- Authority
- CN
- China
- Prior art keywords
- vaginal mucosa
- repair
- mucosa repair
- capsule
- vaginal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000004877 mucosa Anatomy 0.000 title claims abstract description 79
- 230000008439 repair process Effects 0.000 title claims abstract description 69
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims abstract description 23
- 229960003376 levofloxacin Drugs 0.000 claims abstract description 23
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims abstract description 18
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 claims abstract description 18
- 239000000654 additive Substances 0.000 claims abstract description 7
- 230000000996 additive effect Effects 0.000 claims abstract description 7
- 239000003607 modifier Substances 0.000 claims abstract description 5
- 230000001105 regulatory effect Effects 0.000 claims abstract description 3
- 239000002775 capsule Substances 0.000 claims description 27
- 239000000243 solution Substances 0.000 claims description 27
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 26
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 22
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 13
- 241000241413 Propolis Species 0.000 claims description 12
- 229940069949 propolis Drugs 0.000 claims description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 239000011259 mixed solution Substances 0.000 claims description 6
- 238000000465 moulding Methods 0.000 claims description 4
- 238000007711 solidification Methods 0.000 claims description 4
- 230000008023 solidification Effects 0.000 claims description 4
- 238000004140 cleaning Methods 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- 210000004400 mucous membrane Anatomy 0.000 abstract description 22
- 210000001519 tissue Anatomy 0.000 abstract description 18
- 230000017423 tissue regeneration Effects 0.000 abstract description 12
- 206010061218 Inflammation Diseases 0.000 abstract description 11
- 230000004054 inflammatory process Effects 0.000 abstract description 11
- 238000011069 regeneration method Methods 0.000 abstract description 7
- 208000037816 tissue injury Diseases 0.000 abstract description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 4
- 235000015097 nutrients Nutrition 0.000 abstract description 4
- 239000001301 oxygen Substances 0.000 abstract description 4
- 229910052760 oxygen Inorganic materials 0.000 abstract description 4
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 230000008338 local blood flow Effects 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 230000033115 angiogenesis Effects 0.000 abstract description 2
- 230000001939 inductive effect Effects 0.000 abstract description 2
- 230000036770 blood supply Effects 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 38
- 210000004027 cell Anatomy 0.000 description 30
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 17
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 17
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 17
- 230000000052 comparative effect Effects 0.000 description 11
- 238000011282 treatment Methods 0.000 description 10
- 210000003954 umbilical cord Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 230000006378 damage Effects 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 230000003444 anaesthetic effect Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000028709 inflammatory response Effects 0.000 description 5
- 230000007774 longterm Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 210000001215 vagina Anatomy 0.000 description 4
- 102000029816 Collagenase Human genes 0.000 description 3
- 108060005980 Collagenase Proteins 0.000 description 3
- 108010019160 Pancreatin Proteins 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 210000000436 anus Anatomy 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 229960002424 collagenase Drugs 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 229940055695 pancreatin Drugs 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 3
- WXUAQHNMJWJLTG-VKHMYHEASA-N (S)-methylsuccinic acid Chemical compound OC(=O)[C@@H](C)CC(O)=O WXUAQHNMJWJLTG-VKHMYHEASA-N 0.000 description 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 241000257303 Hymenoptera Species 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 239000002870 angiogenesis inducing agent Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 229960004194 lidocaine Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241001313288 Labia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000011382 collagen catabolic process Effects 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- -1 dnase Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000003532 endogenous pyrogen Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 108010052620 leukocyte endogenous mediator Proteins 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- JDRMYOQETPMYQX-UHFFFAOYSA-N monomethyl succinate Chemical compound COC(=O)CCC(O)=O JDRMYOQETPMYQX-UHFFFAOYSA-N 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000009854 mucosal lesion Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960005053 tinidazole Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The embodiment of the invention discloses a vaginal mucosa repair composition and application thereof. The vaginal mucosa repair composition comprises: base solution, additive factors and acid-base modifier, wherein: the additive factors comprise UCMSCs, PDGF, SDF-1 and levofloxacin, and the final concentrations of UCMSCs, PDGF, SDF-1 and levofloxacin are 8×10 respectively 5 ‑1×10 6 2-10ng/ml, 2-5mg/ml; the acid-base regulator is used for regulating the pH value of the vaginal mucosa repair composition to 5.8-6.3. The composition provided by the invention can regulate and control the microenvironment inside tissues, inhibit inflammatory reaction, relieve tissue injury, promote angiogenesis, improve local blood circulation and supply oxygen and nutrient substances, thereby inducing and promoting tissue repair and regeneration to improve the repair condition of mucous membranes.
Description
Technical Field
The embodiment of the invention relates to the technical field of vaginal mucosa repair, in particular to a vaginal mucosa repair composition and application thereof.
Background
The vaginal mucosa is a complex ecological system, and comprises a plurality of components such as bacteria, fungi, viruses, mucus and the like. When the mucous membrane is damaged, the microenvironment is unbalanced, resulting in a change in the microbial community, thereby affecting repair of the mucous membrane. Inflammatory reactions and apoptosis are also caused, and a series of inflammatory mediators, such as cytokines, leukocytes, etc., are released, which cause inflammatory reactions, resulting in increased difficulty in tissue destruction and repair. The mucosal cells undergo apoptosis, resulting in loss of normal physiological function and repair ability of the mucosa. And after the vaginal mucosa is damaged, the repair factors such as enough bioactive factors, cytokines and the like are lacked, which are necessary for cell proliferation and repair, and the lack of the factors can influence the repair of the mucosa.
Therefore, in order to promote repair of vaginal mucosa, it is necessary to improve the repair condition of the mucosa by providing appropriate microenvironment, suppressing inflammatory reaction, promoting cell proliferation, and providing sufficient repair factors, etc.
At present, after the vaginal mucosa is damaged, main treatment means comprise: local disinfection, drug administration and anti-inflammatory treatments such as oral cefalexin and tinidazole have the defects of poor effect and long period, are not suitable for patients with older ages or weaker immunity, and have certain side effects and toxicity of drugs in terms of long-term effect, and can cause drug accumulation and intolerance after long-term use. Thus, improvements to existing vaginal mucosa repair methods are needed.
Disclosure of Invention
Therefore, the embodiment of the invention provides a vaginal mucosa repair composition and application thereof, so as to solve the problems of poor treatment effect, long treatment period, low safety and the like of the traditional vaginal mucosa repair method.
In order to achieve the above object, the embodiment of the present invention provides the following technical solutions:
according to a first aspect of embodiments of the present invention, there is provided a vaginal mucosa repair composition comprising: base solution, additive factors and acid-base modifier, wherein: the additive factors comprise UCMSCs, PDGF, SDF-1 and levofloxacin, and the final concentrations of UCMSCs, PDGF, SDF-1 and levofloxacin are 8×10 respectively 5 -1×10 6 2-10ng/ml, 2-5mg/ml; the acid-base regulator is used for regulating the pH value of the vaginal mucosa repair composition to 5.8-6.3.
UCMSCs, i.e. umbilical cord mesenchymal stem cells, have multidirectional differentiation potential and tissue repair capability, and can be differentiated into various cell types, such as fibroblasts, vascular endothelial cells, smooth muscle cells and the like, so as to promote the repair and regeneration of damaged tissues; it can also secrete various cytokines and growth factors, such as inflammatory factors, transforming growth factor-beta (TGF-beta), epidermal Growth Factor (EGF), etc., which can inhibit inflammatory response, reduce tissue damage, and promote tissue repair; can also secrete angiogenic factors (VEGF) and the like, promote new blood vessel generation, improve local blood circulation, and increase the supply of oxygen and nutrient substances, thereby promoting tissue repair and regeneration. UCMSCs can also regulate immune function, inhibit immune response, reduce inflammatory response, reduce tissue injury degree and promote tissue repair.
PDGF, platelet derived growth factor: involved in cell proliferation, angiogenesis, and collagen synthesis during repair, etc.
SDF-1, a human stromal cell derived factor: is involved in tissue repair and regeneration, and can attract stem cells to migrate to damaged tissues.
Levofloxacin (CAS number: 138199-71-0) is one of quinolone drugs and has good anti-inflammatory effect against escherichia coli, proteus, salmonella and the like. The levofloxacin used in the invention is purchased from Beijing Soy Bao technology Co.
The vagina is a weakly acidic environment, with a pH typically between 4.5 and 5.0, and the optimum pH for cells and related factors is between 7.0 and 7.5. The pH value of the repairing composition is adjusted to be between 5.8 and 6.3 by using the acid-base regulator, so that the repairing composition is easier to recover damaged tissues.
According to the invention, a great deal of research is carried out on the additive factors, and the composition containing UCMSCs, PDGF, SDF-1 and levofloxacin in the final concentration range can effectively regulate and control the micro environment in tissues, inhibit inflammatory reaction, alleviate tissue injury, promote new blood vessel generation, improve local blood circulation, improve the supply of oxygen and nutrient substances, further induce and promote tissue repair and regeneration, and realize excellent mucous membrane repair effect.
Further, the final concentrations of UCMSCs, PDGF, SDF-1 and levofloxacin are 1×10 respectively 6 /ml、5ng/ml、2ng/ml、2.5mg/ml。
Further, the base solution consists of 0.9% NaCl solution and glycerol in a volume ratio of 10-30:1. Wherein, 0.9% NaCl solution (i.e. physiological saline) is the isotonic solvent needed for preparing the cell suspension; the glycerol is used for improving the viscosity between the cell suspension and the propolis, and can also form a protective film on the skin to play a role in moisturizing.
Further, the acid-base modifier is acetic acid.
According to a second aspect of embodiments of the present invention, there is provided the use of a composition as described above in the preparation of a vaginal mucosa repair formulation.
Further, the preparation is a capsule.
According to a third aspect of the embodiment of the present invention, the present invention provides a vaginal mucosa repair capsule, and the preparation method of the vaginal mucosa repair capsule includes the following steps:
1) Dissolving PLGA in methanol to obtain PLGA solution;
2) Dripping the PLGA solution into propolis, and uniformly stirring to obtain a mixed solution;
3) Injecting the mixed solution into a mold, and then performing solidification molding and normal saline cleaning to obtain a capsule;
4) Injecting the vaginal mucosa repair composition as claimed in any one of the above into the capsule to obtain the vaginal mucosa repair capsule.
Propolis is a viscous substance prepared by collecting natural substances such as resin, pollen, plant juice, etc. from bees and combining secretions such as saliva and ferment of bees. Propolis contains multiple active ingredients including flavonoids, phenolic acids, terpenoids, proteins, etc., and has antibacterial, antiinflammatory, antioxidant, antitumor, and immunoregulatory activities. Propolis used in the present invention was purchased from Shanghai Ke Raman reagent Co., ltd (CAS number: 8012-89-3). PLGA, a polylactic acid-glycolic acid copolymer (CAS number 26780-50-7), is a biodegradable polymer commonly used in the preparation of sustained release drug delivery systems. PLGA used in the present invention was purchased from Guangzhou Chemie Biotech Inc. The research shows that the encapsulation of the propolis in PLGA is beneficial to improving the stability of the capsule, thereby prolonging the drug release time.
Further, in step 1), the concentration of the PLGA solution is 0.5 to 1g/ml.
Further, in the step 2), the volume-mass ratio of the PLGA solution to the propolis is 1:2-5.
Further, in the step 3), the solidification forming temperature is 23-28 ℃ and the time is 40-60min.
The embodiment of the invention has the following advantages:
1. the cells and cytokines in the vaginal mucosa repair composition provided by the invention have better biocompatibility with mucosa tissues, can be more effectively acted on the mucosa injury position, and are beneficial to repairing the ulcer surface and accelerating the healing of skin and mucosa wounds.
2. The cells and the cytokines used in the invention can be derived from self stem cells or allogeneic stem cells, and the safety is higher.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below. It will be apparent to those of ordinary skill in the art that the drawings in the following description are exemplary only and that other implementations can be obtained from the extensions of the drawings provided without inventive effort.
FIG. 1 is a diagram of normal rat vaginal mucosa tissue provided by the invention;
FIG. 2 is a diagram of vaginal mucosa tissue of a model rat provided by the invention;
fig. 3 is a graph of vaginal mucosa tissue of rats of experimental group 2 provided by the invention;
fig. 4 is a graph of vaginal mucosa tissue of rats of experimental group 3 provided by the present invention;
fig. 5 is a graph of vaginal mucosa tissue of rats of experimental group 4 provided by the present invention;
fig. 6 is a graph of vaginal mucosa tissue of rats of experimental group 5 provided by the present invention;
fig. 7 is a graph of vaginal mucosa tissue of rats of experimental group 6 provided by the present invention;
fig. 8 is a graph of vaginal mucosa tissue of rats of experimental group 7 provided by the present invention;
FIG. 9 is a graph showing comparison of tumor necrosis factor (TNF-. Alpha.) content provided by the present invention;
FIG. 10 is a graph showing comparison of Vascular Endothelial Growth Factor (VEGF) content provided by the present invention;
FIG. 11 is a graph showing comparison of the content of type I collagenase (COL I) provided by the invention.
Detailed Description
Other advantages and advantages of the present invention will become apparent to those skilled in the art from the following detailed description, which, by way of illustration, is to be read in connection with certain specific embodiments, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
The preparation method of UCMSCs used in the invention is a conventional technical means in the field. As an example, in the following examples and comparative examples, UCMSCs were prepared as follows:
1. preparing materials: umbilical cord tissue, PBS buffer, pancreatin, dnase, DMEM medium, 10% FBS, 1% penicillin/streptomycin.
2. Obtaining umbilical mesenchymal stem cells from the umbilical cord, flushing the umbilical cord mesenchymal stem cells with PBS buffer solution for a plurality of times, and removing blood and cell debris; cutting umbilical cord tissue, adding into digestion solution containing 0.25% pancreatin and 0.05% dnase, and digesting at 37deg.C for 30 min; filtering the digestion solution, centrifuging the precipitate, removing the supernatant, and washing the precipitate for 2-3 times.
3. Umbilical cord mesenchymal stem cells are cultured. Suspending the precipitated cells in DMEM medium, adding 10% FBS and 1% penicillin/streptomycin, and placing at 37deg.C and 5% CO 2 Is cultured in an incubator of (a). The medium was changed every 2-3 days until the cell density reached a certain level.
4. Screening umbilical cord mesenchymal stem cells. The cultured cells were digested with 0.25% pancreatin and 0.05% EDTA, the cell suspension was collected, and the supernatant was removed by centrifugation. The pellet was washed 2-3 times with PBS buffer to remove cell residues and serum components from the medium.
5. Identifying umbilical cord mesenchymal stem cells. The umbilical cord mesenchymal stem cells are identified by a flow cytometry or staining method and the like, and the phenotype and the function of the umbilical cord mesenchymal stem cells are confirmed.
6. When the cells are passaged to the third generation and the cell density reaches 80-90%, trypsin is used for digestion, centrifugation, counting and resuspension, and UCMSCs suspension is obtained for standby.
Example 1
The present example provides a vaginal mucosa repair composition:
pipetting 1X 10 of the contents with a pipette 7 The suspension of UCMSCs cells is centrifuged again, the supernatant is removed, and 8.5ml of 0.9% NaCl solution, 0.5ml of glycerol and 1ml of acetic acid are added for resuspensionCells, the cell concentration was 1X 10 6 And (3) per ml, wherein the pH value of the system is 5.8, PDGF, SDF-1 and levofloxacin are added, and the liquid is mixed uniformly by gentle suction, wherein the final concentration of PDGF, SDF-1 and levofloxacin is 5ng/ml, 2ng/ml and 2.5mg/ml.
Example 2
The present example provides a vaginal mucosa repair composition:
pipetting 1X 10 of the contents with a pipette 7 The suspension of UCMSCs cells was centrifuged again, the supernatant was removed, and 8.8ml of 0.9% NaCl solution, 0.4ml of glycerol, and 0.8ml of acetic acid were added to resuspend the cells to a cell concentration of 1X 10 6 And (3) per ml, wherein the pH value of the system is 6.0, PDGF, SDF-1 and levofloxacin are added, and the liquid is mixed uniformly by gentle suction, wherein the final concentration of PDGF, SDF-1 and levofloxacin is 10ng/ml, 10ng/ml and 2mg/ml.
Example 3
The present example provides a vaginal mucosa repair composition:
pipetting 1X 10 of the contents with a pipette 7 The suspension of UCMSCs cells was centrifuged again, the supernatant was removed, and the cells were resuspended in 9.3ml of 0.9% NaCl solution, 0.2ml of glycerol, 0.5ml of acetic acid to a cell concentration of 1X 10 6 And (3) per ml, wherein the pH value of the system is 6.3, PDGF, SDF-1 and levofloxacin are added, and the liquid is mixed uniformly by gentle suction, wherein the final concentration of PDGF, SDF-1 and levofloxacin is 8ng/ml, 2ng/ml and 5mg/ml.
Example 4
The present example provides a vaginal mucosa repair capsule prepared by injecting the composition of example 1 into a capsule, comprising the following specific steps:
(1) PLGA is dissolved in methanol to obtain PLGA solution with the concentration of 0.5 g/ml;
(2) Dripping 1ml of PLGA solution obtained in the step (1) into 2.5mg of propolis, and uniformly stirring to enable PLGA to wrap the propolis, thereby obtaining a mixed solution;
(3) Injecting the mixed solution obtained in the step (2) into a mold, solidifying and molding at 25 ℃, taking out the solidified gel block after 40min, and then cleaning with normal saline to obtain a single capsule with the weight of 0.5 g;
(4) Sucking 0.2ml of the composition of the example 1 by a syringe, and injecting the composition into the capsule of the step (3) to obtain the vaginal mucosa repair capsule.
Examples 5 to 6
The compositions of examples 2-3 were each formulated into vaginal mucosa repair capsules according to the procedure of example 4.
Comparative example 1
This comparative example provides a vaginal mucosa repair capsule which differs from example 4 only in the vaginal mucosa repair composition. The vaginal mucosa repair composition used in this comparative example:
pipetting 1X 10 of the contents with a pipette 7 The suspension of UCMSCs cells was centrifuged again, the supernatant was removed, and 8.5ml of 0.9% NaCl solution, 0.5ml of glycerol, and 1ml of acetic acid were added to resuspend the cells to a cell concentration of 1X 10 6 And (3) per ml, wherein the pH value of the system is 5.8, and then bFGF, EGF and levofloxacin are added, and the liquid is mixed uniformly by gentle suction, wherein the final concentration of bFGF, EGF and levofloxacin is 5ng/ml, 2ng/ml and 2.5mg/ml.
Comparative example 2
This comparative example provides a vaginal mucosa repair capsule which differs from example 4 only in the vaginal mucosa repair composition. The vaginal mucosa repair composition used in this comparative example:
pipetting 1X 10 of the contents with a pipette 7 The suspension of UCMSCs cells was centrifuged again, the supernatant was removed, and 8.5ml of 0.9% NaCl solution, 0.5ml of glycerol, and 1ml of acetic acid were added to resuspend the cells to a cell concentration of 1X 10 6 The pH value of the system is 5.8, PDGF, VEGF and levofloxacin are added, and the liquid is mixed uniformly by gentle suction, wherein the final concentration of PDGF, VEGF and levofloxacin is 5ng/ml, 2ng/ml and 2.5mg/ml.
Comparative example 3
This comparative example provides a vaginal mucosa repair capsule which differs from example 4 only in the vaginal mucosa repair composition. The vaginal mucosa repair composition used in this comparative example:
suction with a pipetteTaking 1×10 of the extract 7 The suspension of UCMSCs cells was centrifuged again, the supernatant was removed, and 8.5ml of 0.9% NaCl solution, 0.5ml of glycerol, and 1ml of acetic acid were added to resuspend the cells to a cell concentration of 1X 10 6 And (3) per ml, wherein the pH value of the system is 5.8, PDGF, SDF-1 and levofloxacin are added, and the liquid is mixed uniformly by gentle suction, wherein the final concentration of PDGF, SDF-1 and levofloxacin is 1ng/ml, 12ng/ml and 2.5mg/ml.
Test example 1
1. Preparation of rat vaginal mucosa injury model
1. Preparation of tools and materials: surgical knife, forceps, syringe, sterile normal saline, 2% lidocaine anesthetic, 2% methyl succinate anesthetic, disinfectant, sterile glove, sterile mask, sterile surgical gown, etc.
2. Female rats are selected, the weight of the rats is between 200 and 250g, and 2% lidocaine anesthetic solution is injected into the rats by a syringe so as to enable the rats to be in an anesthetic state.
3. The pudendum was washed with disinfectant, the labia were separated with forceps, and an incision of about 1-2mm was made at the vaginal orifice with a scalpel.
4. 2% methyl succinate anesthetic (available from Shandong Jinbang Biotechnology Co., ltd., CAS number 3878-55-5) was injected by syringe, and the liquid was slowly injected into the vagina to damage the mucous membrane.
5. The rat was recovered under anesthesia, returned to the cage, and the recovery was observed.
6. The vaginal mucosa tissue of the rat is taken 24 hours after the operation, and the damage condition is observed under the microscope and 20 times of objective lens.
7. Identification of successful modeling
7.1 Visual inspection: the vaginal orifice of the rat is widened by using forceps, the original state of local tissues of the normal rat can be observed to be soft, moist and smooth by irradiation of a flashlight, and inflammation symptoms such as red swelling, exudation and the like of the model rat are observed, and the anus temperature of the normal rat is detected by using an anus temperature detector, and the anus temperature of the model rat is between 38.4 and 39.8 ℃.
7.2 Observation under 20 times of microscope objective lens: deeply anesthetizing the rat, and taking vaginal mucosa tissue of the rat. When observed under a microscope, the vaginal mucosa of a normal rat is curved and presents a morphology similar to an S shape, as shown in figure 1. The vaginal mucosa of the injured rat is organized into long strips, the S-shaped structure is straightened, thickened and mostly disappears into fibrous scar structure as shown in figure 2.
2. Experimental grouping
42 vaginal mucosa injury model rats were selected and randomly divided into experimental groups 1-7, each group of 6 rats. Wherein, the experimental group 1 was not treated with any drug, the experimental groups 2 to 4 were treated with the vaginal mucosa repair capsules of examples 4 to 6, respectively, the experimental groups 5 to 7 were treated with the vaginal mucosa repair capsules of comparative examples 1 to 3, respectively, while the Sham group (normal rats, 6) was set for control.
The treatment method comprises the following steps: the vaginal mucosa repair capsule is slowly pushed into the vaginal orifice, and the vaginal mucosa tissues can slowly absorb the propolis blocks along with the time, so that cells can also play a role in the vagina for a long time, and the treatment effect is achieved. Daily administration, before administration, the vaginal orifice of the rat is flushed with physiological saline.
3. Effect verification
1. 7d after treatment, taking vaginal mucosa tissue of the rat, and observing the mucosa repair condition under a microscope 20 times of an objective lens.
The results show that: the rats of experimental groups 5-7 had poor recovery from vaginal mucosal tissue injury, and the fibrous scar tissue was reduced compared to the rats of the model group, indicating that there was little effect, but still more severe mucosal tissue loss, dishing (see fig. 6-8). The vaginal mucosa tissue of rats in experimental groups 3-4 showed tissue loss and dishing after 7d, but compared with the model mice before injury, the mucosa tissue structure was slightly restored (see fig. 4 and 5); the vaginal mucosal tissue of the rats in the experimental group 2 is obviously recovered, the mucosal tissue structure reappears an S-shaped curve, the fibrous scar-like tissue disappears, and the missing mucosal tissue is recovered (see figure 3).
2. Changes in associated factors within the vaginal mucosa
After 7d treatment, the vaginal mucosal tissue of each group of rats was collected and weighed, PBS (pH 7.4) was added in a proportion of PBS (ml): tissue (g) =9:1. The collected tissue was then placed in liquid nitrogen for 1min to facilitate milling and homogenized by hand homogenizer. 3000 rpm, centrifuging for 20 minutes, collecting supernatant, and collecting vaginal mucosa tissue from 3 animals selected in each group. And (5) after sub-packaging, one part is to be detected, and the rest is rapidly frozen and stored for later use by using liquid ammonia.
After tissue injury, the body can trigger inflammatory reaction, and the long-term chronic physiological reaction can lead to the phenomena of vasodilation, exudation, leukocyte infiltration, inflammatory cytotoxicity, collagen degradation and the like. Inflammation elimination, neovascularization, and adsorption regeneration of extracellular matrix are one of the key steps in tissue repair. In the damaged area, the body releases angiogenic factors (VEGF) to promote vascular formation to provide oxygen, nutrients and cellular migration pathways. In addition, synthesis and deposition of collagen and other extracellular components can provide support for regeneration of tissue structures. The effect of the treatment was evaluated by the expression of tumor necrosis factor alpha (TNF-alpha), vascular Endothelial Growth Factor (VEGF) and collagen type I (COL I) in the vaginal mucosal tissue.
In vaginal mucosal lesion disease studies, over time, large amounts of pro-inflammatory factors such as TNF- α, IL-1β,and the like, seriously influences the microenvironment of tissues in the vagina, so that the damaged mucous membrane tissues are difficult to recover, and the illness state is aggravated. Among them, TNF- α is a cell signaling protein (cytokine) involved in systemic inflammation, is a major cytokine constituting an acute-phase inflammatory response, and is also an endogenous pyrogen capable of inducing an inflammatory response such as fever, cell death, cachexia, etc., and is important in the inflammatory response. Therefore, the invention detects the TNF-alpha expression condition of the rat mucous membrane tissues of each group, and the result is shown in figure 9, the expression quantity of TNF-alpha of the experimental groups 2-4 is lower than that of the experimental groups 5-6 and is obviously lower than that of the experimental group 1 and basically equivalent to that of a sham group, and the vaginal mucous membrane repair composition provided by the embodiment of the invention is more beneficial to reducing tumor necrosis factorThe expression level of TNF-alpha further promotes rapid recovery of the intravaginal tissue microenvironment, wherein example 1 works best.
Vascular Endothelial Growth Factor (VEGF), after vaginal mucosal injury, changes in the tissue microenvironment occur in a range of ways, where neovascularization is one of the key factors in mucosal repair. Therefore, the invention detects the VEGF expression condition of the rat mucous membrane tissues of each group, and the result is shown in fig. 10, the VEGF expression quantity of the experimental groups 2-4 is higher than that of the experimental groups 5-6 and is obviously higher than that of the experimental group 1, and the above contents indicate that the vaginal mucous membrane repair composition provided by the embodiment of the invention is more favorable for improving the expression quantity of Vascular Endothelial Growth Factor (VEGF), and is more favorable for promoting mucous membrane repair, wherein the VEGF factor expression quantity of the experimental group 2 is slightly smaller than that of the Sham group, because a longer period is possibly caused by the generation of new blood vessels, the VEGF factor expression quantity of the experimental group 2 after treatment is different from that of the vascular endothelial growth factor in the mucous membrane tissues of normal rats, but the effect is optimal.
Type I collagen (COL I) causes degradation of type I collagenase due to the blockage of proliferation and migration of epithelial and mesenchymal cells in vaginal mucosal tissue caused by long-term inflammation of the post-injury area. Therefore, according to the detection of COL I expression conditions of rat mucous membrane tissues in each group, the results are shown in fig. 11, the COL I expression level of experimental groups 2-4 is higher than that of experimental groups 5-7 and is obviously higher than that of experimental group 1, and the above shows that the vaginal mucous membrane repair composition provided by the embodiment of the invention can effectively inhibit inflammation, and the filling and repair of damaged areas are realized through the activation of type I collagenase and the increase of secretion. Among them, COL I factor expression of experimental group 2 was close to that of the Sham group, indicating that the composition of example 1 was most effective.
While the invention has been described in detail in the foregoing general description and specific examples, it will be apparent to those skilled in the art that modifications and improvements can be made thereto. Accordingly, such modifications or improvements may be made without departing from the spirit of the invention and are intended to be within the scope of the invention as claimed.
Claims (10)
1. A vaginal mucosa repair composition, wherein the vaginal mucosa repair composition comprises: base solution, additive factors and acid-base modifier, wherein:
the additive factors comprise UCMSCs, PDGF, SDF-1 and levofloxacin, and the final concentrations of UCMSCs, PDGF, SDF-1 and levofloxacin are 8×10 respectively 5 -1×10 6 2-10ng/ml, 2-5mg/ml; the acid-base regulator is used for regulating the pH value of the vaginal mucosa repair composition to 5.8-6.3.
2. The vaginal mucosa repair composition according to claim 1, wherein the final concentration of UCMSCs, PDGF, SDF-1 and levofloxacin is 1 x 10, respectively 6 /ml、5ng/ml、2ng/ml、2.5mg/ml。
3. The vaginal mucosa repair composition of claim 1, wherein the base fluid consists of a 0.9% NaCl solution and glycerin in a volume ratio of 10-50:1.
4. The vaginal mucosa repair composition of claim 1, wherein the acid-base modifier is acetic acid.
5. Use of a composition according to any one of claims 1-4 for the preparation of a vaginal mucosal repair formulation.
6. The use according to claim 5, wherein the formulation is a capsule.
7. The preparation method of the vaginal mucosa repair capsule is characterized by comprising the following steps of:
1) Dissolving PLGA in methanol to obtain PLGA solution;
2) Dripping the PLGA solution into propolis, and uniformly stirring to obtain a mixed solution;
3) Injecting the mixed solution into a mold, and then performing solidification molding and normal saline cleaning to obtain a capsule;
4) Injecting the vaginal mucosa repair composition of any one of claims 1-4 into said capsule to obtain said vaginal mucosa repair capsule.
8. The vaginal mucosa repair capsule of claim 7, wherein in step 1), the concentration of the PLGA solution is 0.5-1g/ml.
9. The vaginal mucosa repair capsule of claim 7, wherein in step 2), the volume to mass ratio of PLGA solution to propolis is 1:2-5.
10. The vaginal mucosa repair capsule according to claim 7, wherein in step 3), the solidification molding temperature is 23-28 ℃ and the time is 40-60min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311071998.XA CN116803417B (en) | 2023-08-24 | 2023-08-24 | Vaginal mucosa repair composition and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311071998.XA CN116803417B (en) | 2023-08-24 | 2023-08-24 | Vaginal mucosa repair composition and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116803417A CN116803417A (en) | 2023-09-26 |
| CN116803417B true CN116803417B (en) | 2023-10-27 |
Family
ID=88079704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311071998.XA Active CN116803417B (en) | 2023-08-24 | 2023-08-24 | Vaginal mucosa repair composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116803417B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118161598B (en) * | 2024-05-11 | 2024-07-19 | 北京益华生物科技有限公司 | Composition for treating colpitis and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106730013A (en) * | 2016-12-06 | 2017-05-31 | 徐妍 | For preventing Asherman's syndrom and the cell preparation of endometrial impairment reparation and preparation method thereof |
| CN108619086A (en) * | 2018-07-04 | 2018-10-09 | 天津昂赛细胞基因工程有限公司 | A kind of Cellular gels preparation for treating tissue damage and application thereof and the active gel solution of holding freeze-stored cell used |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3135658A1 (en) * | 2020-12-24 | 2022-06-24 | Riam Shammaa | Mesenchymal stem cells for treatment of skin disorders and skin problems |
-
2023
- 2023-08-24 CN CN202311071998.XA patent/CN116803417B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106730013A (en) * | 2016-12-06 | 2017-05-31 | 徐妍 | For preventing Asherman's syndrom and the cell preparation of endometrial impairment reparation and preparation method thereof |
| CN108619086A (en) * | 2018-07-04 | 2018-10-09 | 天津昂赛细胞基因工程有限公司 | A kind of Cellular gels preparation for treating tissue damage and application thereof and the active gel solution of holding freeze-stored cell used |
Non-Patent Citations (2)
| Title |
|---|
| A new material for tissue engineered vagina reconstruction: Acellular porcine vagina matrix;Jing-Kun Zhang等;《BIOMEDICAL MATERIALS RESEARCH A》;第105卷(第7期);第1949-1959页 * |
| Expression of platelet-derived growth factor-B mRNA during vaginal vs. dermal incisional wound healing in the rabbit;Yoram Abramov等;《European Journal of Obstetrics & Gynecology and Reproductive Biology》;第162卷(第2期);第216-220页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116803417A (en) | 2023-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dadkhah Tehrani et al. | A review on modifications of amniotic membrane for biomedical applications | |
| CN112601533B (en) | Composition for preventing or treating arthritis comprising culture solution containing stem cell-derived exosomes as active ingredient | |
| Benjamin et al. | Myofibroblastic contraction in spontaneous regression of multiple congenital mesenchymal hamartomas | |
| US8911963B2 (en) | Conditioned medium obtained from stem cells and its use in therapy | |
| US20120189586A1 (en) | Human Placental Derived Extracellular Matrix and Uses Therof | |
| CN116803417B (en) | Vaginal mucosa repair composition and application thereof | |
| CN113509590B (en) | Wound dressing with exosome combined with hyaluronic acid and preparation method and application thereof | |
| CN111437431A (en) | Exosome hydrogel wound dressing and preparation method thereof | |
| KR102431839B1 (en) | Composition for wound treatment or tissue regeneration comprising a mixture of poloxamer, hyaluronic acid, and extracellular matrix and use thereof | |
| JP2010529988A (en) | Human umbilical cord tissue-derived cell composition for treatment of incontinence | |
| WO2024077893A1 (en) | Preparation of combination of stem cells and hydrogel as biomaterial and use of combination in spinal cord injuries | |
| WO2023072161A1 (en) | Composition containing mesenchymal stem cells and hydrogel, and use thereof | |
| CN103349798A (en) | Compound active amnion material, preparation method and application thereof and compound active amnion uterine cavity repair stent | |
| Tian et al. | Repair of urethral defects by an adipose mesenchymal stem cell‑porous silk fibroin material | |
| CN107488627B (en) | Biological gel for treating refractory skin damage and application thereof | |
| Ding et al. | Galectin-1-induced skeletal muscle cell differentiation of mesenchymal stem cells seeded on an acellular dermal matrix improves injured anal sphincter | |
| CN104399120A (en) | Preparation method of collagen membrane and collagen membrane thereof | |
| Ge et al. | Combination therapy using multifunctional dissolvable hyaluronic acid microneedles for oral ulcers | |
| US20210069257A1 (en) | Composition and method for treating skin condition | |
| Kafili et al. | Amnion-derived hydrogels as a versatile platform for regenerative therapy: from lab to market | |
| CN110772534A (en) | Application of multisystem differentiation sustained stress cells in preparation of anti-inflammatory drugs | |
| JP5251873B2 (en) | Use of adipose tissue cell fraction for tissue regeneration after irradiation | |
| CN107469065B (en) | Application of snake venom-like three-peptide in preparation of medicine for treating skin ulcer | |
| Lam et al. | Intrauterine Infusion of Leukocyte Platelet-rich Plasma Enhances Fertility Outcomes in the Murine Model of Asherman\'s Syndrome | |
| CN118141900B (en) | Stem cell factor composition and sustained release agent for repairing endometrial injury and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |